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Abstract
Affibodies are a class of polypeptide ligands that are potential candidates for cell- or tissue-
specific targeting of drug-encapsulated controlled release polymeric nanoparticles (NPs). Here we
report the development of drug delivery vehicles comprised of polymeric NPs that are surface
modified with Affibody ligands that bind to the extracellular domain of the trans-membrane
human epidermal growth factor receptor 2 (HER-2) for targeted delivery to cells which over
express the HER-2 antigen. NPs lacking the anti-HER-2 Affibody did not show significant uptake
by these cells. Using paclitaxel encapsulated NP-Affibody (1 wt% drug loading), we demonstrated
increased cytotoxicity of these bioconjugates in SK-BR-3 and SKOV-3 cell lines. These targeted,
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Drug encapsulated controlled release nanoparticles (NPs) have the potential to improve the
current cancer chemotherapies by increasing drug efficacy, lowering drug toxicity, and
maintaining a relatively high concentration of drug at the site of interest [1-3]. Encapsulating
drugs within NPs can improve the solubility and pharmacokinetics of drugs, and, in some
cases, enable the further clinical development of new chemical entities that have stalled
because of poor pharmacokinetic properties. The breakthrough potential of cancer
nanotechnology is becoming more apparent with several examples of non-targeted NP
platforms in clinical practice today. These include Abraxane (paclitaxol-albumin) [4], Doxil
(doxorubicin-liposomes) [5], DaunoXome (daunorubicin-liposomes)[6], Cyclosert
(camptothecin-cyclodextrin) [7] and Genexol-PM [paclitaxolmethoxy-polyethyleneglycol-
poly(D,L-Lactide)] [8]. The functionalization of non-targeted NPs with ligands that bind to
the extracellular domain of tumor-associated trans-membrane antigens may further increase
the therapeutic index of cytotoxic drugs by differentially targeting drugs to the diseases
cells.
The first examples of targeted nanoparticles were reported in 1980 and despite nearly 3
decades of research, targeted nanoparticles have made a limited impact on human health.
This is in part because the optimal biophysicochemical properties of the nanoparticles,
including the choice of a suitable ligand for targeting has remained elusive [9-11]. These
include the utilization of targeting approaches that go beyond antibodies which have several
known drawbacks including their large hydrodynamic size which limits both intratumoral
uptake and homogeneous distribution in the tumor adversely affecting pharmacokinetic
properties. Further, the use of an antibody as a component of a multifunctional nanoparticle
adds an additional level of complexity to the scale-up and manufacturing of the resultant
targeted nanoparticles. There is a clear need for new methods of targeting that are
compatible with the size of nanoparticles and their manufacturing. Additionally, while
monoclonal antibodies have shown some promise their effects tend to be variable and
ultimately not curative. Attempts to develop immunoconjugates, which add the therapeutic
benefit of a drug, toxin, or radionuclide, have not met with much success either probably
due to low drug content per antibody molecule. However, the combination of the targeting
capabilities of an antibody, without the inherent limitations of antibodies [12] as mentioned
above, and a controlled release system utilizing a payload consisting of a small molecule
chemotherapeutic may prove to be advantageous.
The anti-HER-2 Affibody has many merits as a targeting ligand in contrast to an anti-HER-2
monoclonal antibody. Its small size (Molecular weight ~ 15 kDa) results in a favorable ratio
of binding site to ligand size, bearing in mind that the molecular weight of an anti-HER-2
monoclonal antibody is typically about 150 kDa; it promotes an endocytosis dependent
internalization mechanism [13-16]; it has a functional end group distanced from its active
site for chemical conjugation; it has high in vitro and in vivo stability; and the total chemical
synthesis allows facile large scale production of the Affibody. The anti-HER-2 Affibody (Z-
HER2: 342 Affibody) has shown high binding affinity (kD ~ 22 pM) to the recombinant
extracellular domain of the protein HER-2 (HER-2-ECD) [17, 18]. In addition, Orlova et al.
[17] has shown that this class of molecules can selectively bind to HER-2 over-expressing
cell lines (SK-BR-3 and SK-OV-3). All of these characteristics make Affibody a potentially
viable ligand for targeted drug delivery.
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To develop HER-2 targeted drug encapsulated NPs, we conjugated the anti-HER-2 Affibody
to the thiol-reactive maleimide of the PLA-PEG-Maleimide (PLA-PEG-Mal) copolymer of
the previously formed NPs through a stable thioether bond and evaluated the targeting
specificity and efficacy using fluorescent microscopy. Subsequently, we encapsulated
paclitaxel into the targeted polymeric NPs and examined whether this system could increase
the drug cytotoxicity in HER-2 positive cell lines: SK-BR-3 and SK-OV-3. We chose to
deliver the taxane paclitaxel due to its poor water solubility which results in a reduced
therapeutic index for intravenous administration of the free drug in a clinical setting.
We first synthesized a copolymer comprised of a hydrophobic block, poly (D,L lactic acid),
and a hydrophilic block, poly(ethylene glycol) with a maleimide terminal group (PLA-PEG-
Mal). Then the copolymers form negatively charged NPs with a core-shell structure in an
aqueous environment via the nanoprecipitation method. The hydrophobic core of the NPs is
capable of carrying pharmaceuticals, especially those with poor water solubility. The
hydrophilic shell not only provides a “stealth” layer [19], together with the surface charge
property (Zeta potential) = - 10 mV ± 5 mV) [20, 21], to improve the stability and the
circulation half-time of these drug delivering NPs, but also functional maleimide groups for
Affibody conjugation (Figure 1A). Lack of protein adsorption in solutions including 10%,
20% and 100% serum (data not shown) demonstrated the stability of NP size (< 100 nm).
We also evaluated the freeze-drying process for storing the nanoparticles in a dry state, as
described previously [22]. We were able to reconstitute nanoparticles with a similar original
size after lyophilization, confirming the stability of this type of carrier to this process.
The anti-HER-2 Affibody molecule was previously selected against the extracellular domain
of the HER-2 protein [23] and further modified by affinity maturation and dimerization [14,
18]. The anti-HER-2 Affibody is commercially available and has been shown to have high
binding specificity and affinity in vitro and in vivo as a targeted imaging agent [17, 24-26].
Therefore, the multiple advantages of the combination of biodegradable polymeric NPs and
targeting anti-HER-2 Affibody molecules led to our interest in developing a a targeted,
controlled release drug delivery system for cancer therapy aimed at HER-2 positive cells.
Particle size and surface charge (Zeta potential) of PLA-PEG-Mal NPs both with and
without Affibody were characterized using laser light scattering, ZetaPALS system and
electron microscopy (Figure 1A). The addition of Affibody molecules on the surface of the
NPs did not significantly affect the size, size distribution and surface charge of the NPs (NP
=70 ± 5nm, NP-Affibody 85 ± 5nm). The chemical conjugation of the Affibody molecules
on the surface of the PLA-PEG-Mal NPs was confirmed using UV imaging (Figure 1A) and
proton nuclear magnetic resonance spectroscopy in d-DMSO (1H-NMR) (Figure 1B). To
visualize the presence of Affibody molecules on the NPs, we labeled Affibody molecules
with the fluorescence probe, Alexa Fluor 532, and subsequently conjugated them to the
PLA-PEG-Mal NPs with different molar ratios of Affibody:PLA-PEG-Mal (0, 1, 2, 5, 20%).
The NP-Affibody bioconjugates were then exposed under UV lamp to observe their
fluorescence signals. As shown in Figure 1B, no fluorescence signal was observed from the
NPs without fluorescently labeled Affibody, however, the fluorescence intensity from those
NPs with fluorescent Affibody continuously enhances with the increase of Affibody:PLA-
PEG-Mal molar ratio. The 1H-NMR spectrum of the purified PLA-PEG-Affibody in d-
DMSO showed the characteristic peaks of PLA-PEG at chemical shift of δ~ 1.4 ppm (–CH3
of the PLA backbone), δ ~ 3.6 ppm of (-CH2 of the PEG backbone) and δ~ 5.2 ppm (-CH of
the PLA backbone) (Figure 1B). Additionally, we observed the characteristic peaks of the
Affibody molecule in the chemical shift region of δ= 7-8 ppm that represents the amide
bonds (NH-CO) within the Affibody polypeptide molecule. The NMR results suggest
successful conjugation of the Affibody on the surface of PLA-PEG-Mal NPs.
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We next demonstrated the efficient binding and internalization of targeted NP-Affibody
bioconjugates to HER-2 positive cancer cells using three cell lines: Capan-1 (Figure 2-B1),
SK-BR-3 (Figure 2-B2), and SK-OV-3 (Figure 2-B3). After incubating NBD dye
encapsulated NP-Affibody bioconjugates with the cells for 2 hr at 37°C and removing the
excess bioconjugates, we observed a large amount of green dots in a punctuate pattern inside
the targeted cells, suggesting an efficient targeting and internalization mechanism of the ~80
nm NP-Affibody bioconjugates to the HER-2 positive cells. In contrast, untargeted PLA-
PEG NPs were slightly taken up by the cell lines after the same duration of incubation
(Figure 2 A1-A3). To minimize cell passage effect on the observed results, this experiment
was repeated four times with different cell passages and all of them gave the same
observations. We also verified the cellular localization of the NP-Affibody bioconjugates
using a z-axis scanning fluorescent microscopy and 3D image reconstitution. The rotated
cross section of the 3D reconstitution images of a SK-BR-3 cell demonstrated the
internalization of targeted NP-Affibody bioconjugates to the cell (Figure 3).
Orlova et al. [18] have shown the binding ability of Anti-HER-2 Affibody within 1 hr using
immunofluorescence method. Our results are consistent with their findings and suggest a
receptor mediated endocytosis mechanism. Internalization through an endocytosis
mechanism has been previously described for anti-HER-2 monoclonal antibodies [27, 28]
and is consistent with the kinetics of our targeted NPs entering the cells within 2 hours.
Similarly, targeted drug delivery using RGD peptide sequences to integrins has also shown
efficient binding and internalization in multiple types of cancers. In addition to efficient
binding and internalization, the anti-HER-2 approach also offers improved cancer disease
specificity with high affinity to HER-2 cell membrane receptors expressed in multiple types
of cancers compared to RGD [29] .We prepared drug-containing and drug free Nps and
targeted nanoparticles to evaluate their differential cytotoxicity using in vitro cell viability
assay (MTS assays) with breast cancer and ovarian cancer cells (SK-BR-3; SK-OV-3),
which over-express the HER-2 cell membrane receptors. In this study, we incubated various
NP formulations with SK-BR-3 and SK-OV-3 cancer cells for 2 hours in optimem, washed
cells with PBS to remove excess of NPs, and supplemented with fresh cell growth medium.
We further incubated the cells for 3 days before using the MTS assay to quantify cell
viability which was normalized to that of the cells in the absence of NPs.
The results showed that drug encapsulated targeted NPs had the highest cytotoxicity to both
SK-BR-3 and SK-OV-3 cell lines; cell viability was 70 ± 5 % and 59 ± 5 %, respectively
(Figure 4). The ANOVA test indicated that the cell viability of drug containing targeted NPs
differed significantly from that of drug containing NPs (p<0.05). In contrast, free drug and
NPs without encapsulated drugs are not toxic to both cell lines. These results are consistent
with our previous studies using targeted NP-aptamer bioconjugates to deliver drugs to
prostate cancer cells [30-33]. Therefore, this NP-Affibody bioconjugate system holds
potential to be used as a biocompatible and biodegradable targeted drug delivery platform
for multiple types of cancer therapeutics. Further, the modularity of the delivery system
allows for tuning of the various parameters of the bioconjugates, such as NP size, surface
charge and Affibody packing density, in order to optimize the drug delivery
pharmacokinetics and its targeting efficiency for optimum specific therapeutic applications.
In summary, herein we report to our knowledge the first example of a targeted controlled
release NP-Affibody bioconjugate for drug delivery to HER-2 positive cancer cells. Using
FDA (Food Drug and Administration) approved polymers to form nanoparticles, we have
demonstrated that the nanoparticle-Affibody bioconjugates were specifically and efficiently
internalized to HER-2 positive cancer cells such as ovarian, breast and pancreatic cancer
cells, thereby providing a promising way to deliver chemotherapeutic drugs to the cancer
cells in a selective manner. This HER-2 targeted drug delivery platform can be tuned to
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encapsulate multiple types and combinations of drugs, increase drug loading, and optimize
the surface coverage of the Affibody targeting ligands for specific therapeutic applications.
Additional in vivo biodistribution and efficacy studies are needed to further evaluate the
potential of the nanoparticle-Affibody bioconjugates for each therapeutic application as a
systemic or locally administered drug delivery system.
Experimental Section
Nanoparticle characterization
Size (diameter) and Zeta-potential (surface charge) of NPs were evaluated by Quasi-elastic
laser light scattering (QELS) using a ZetaPALS dynamic light-scattering detector (15 mW
laser, incident beam = 676 nm; Brookhaven Instruments, Holtsville, NY). 200 μg of
nanoparticles were dispersed in solution (~ 2ml) and measurements were performed in
triplicate at room temperature.
Conjugation and Characterization of nanoparticle-Affibody bioconjugates
PLA-PEG-Mal polymeric NPs were incubated under stirring conditions with the Anti-
HER-2 Affibody molecules (15kDa) at a molar ratio of Affibody:PLA-PEG-Mal of 5 % to
form a stable bioconjugate. The NP-Affibody bioconjugates were purified to remove free
Affibody molecules using Amicon Ultra centrifuge device (100 kDa molecular weight size
exclusion). Subsequently, the thioether bond formation between the PLA-PEG-Mal NPs and
the Affibody molecules was characterized using proton nuclear magnetic resonance (1H-
NMR, 600 MHz, Bruker Advance). Additionally, the chemical attachment of the fluorescent
Affibody was confirmed using an Ultra Violet Imaging system (Kodak Electrophoresis
Documentation and Analysis System 120). The Affibody molecule was fluorescently labeled
with a red fluorescent probe, Alexa Fluor 532 (Invitrogen), purified and subsequently
conjugated to PLA-PEG-Mal polymeric NPs at different molar ratios of Affibody:PLA-
PEG-Mal ranging from 0 to 20 % (molar ratio). Then the purified NP-Affibody bioconjugate
suspensions were imaged using a UV Kodak camera assisted with a red filter to show the
visible effect of the fluorescent Affibody conjugated on non-fluorescent polymeric NPs.
Uptake assays of targeted and untargeted nanoparticles
The human ovarian adenocarcinoma (SK-OV-3; ATCC), human breast adenocarcinoma
(SK-BR-3; ATCC), and human pancreatic adenocarcinoma (Capan-1, ATCC) were the
HER-2 positive cell lines used for cytotoxicity and uptake efficacy studies of the NP-
Affibody bioconjugates. HER-2 positive cell lines were grown in chamber slides (Cab-
TekII, 8 wells; Nunc) within their growth medium (Modified McCoy's 5a (ATCC)
supplemented with 100 units/ml aqueous penicillin G, 100 ug/ml streptomycin, and 10%
FBS) to 70% confluence in 24 h (i.e., 50,000 cells/cm2) in 5 % CO2 incubator. On the day of
the experiment, cells were washed with pre-warmed PBS and incubated with pre-warmed
phenol-red–reduced OptiMEM media for 30 minutes, before adding 50 μg of NPs or NP-
Affibody bioconjugates loaded with same amount of green fluorescent NBD dye (4-
fluoro-7-nitrobenz-2-oxa-1,3-diazole). NP formulations were incubated with cells for 2
hours at 37°C, washed with PBS three times, fixed with 4% paraformaldehyde, blocked for
30 minutes at room temperature with 1 % BSA/PBS, permeabilized with 0.01 % Triton-X
for 3 minutes, counterstained with Alexa-Fluor Phalloidin-Rhodamine (cytoskeleton
staining), 4’,6-diamidino-2-phenylindole (DAPI, nucleus staining), mounted in fluorescence
protecting imaging solution, and visualized using fluorescent microscopy (DeltaVision
system; Olympus IX71). Digital images of green, red and blue fluorescence were acquired
along the z-axis at 0.2 μm intervals using 60X oil immersion objective and DAPI, FITC and
Rhodamine filters respectively. Images were overlaid, deconvoluted and 3D reconstruction
was performed using Softwork software for acquisition and analysis.
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In vitro cellular toxicity assay of paclitaxel encapsulated into targeted and untargeted NPs
SK-BR-3 and SK-OV-3 were grown in 96-well plates at concentrations leading to 70%
confluence in 24 h (i.e. 50,000 cells/cm2). Defined amounts of paclitaxel were encapsulated
into targeted and non-targeted nanoparticles (1 % wt/wt) and incubated with cell lines (5 ug
Paclitaxel/well) in OptiMEM for two hours. Next, cells were washed and fresh media was
supplemented. The cells were then allowed to grow for 72 hours and cell viability was
assessed colorimetrically with MTS reagents (Invitrogen).
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A) Schematic diagram of the formation of drug encapsulated PLA-PEG-Mal nanoparticle-
Affibody bioconjugates. Nanoparticle's size diameter (< 100 nm) and distribution was
visualized by electron microscopy. The hydrophilic polyethyleneglycol (PEG) chains on the
surface reduce the protein absorption on the hydrophobic polymeric surface to form
“stealth” nanoparticles. Direct visualization of Affibody conjugation on the surface of the
nanoparticle was carried out using fluorescent image of fluorescent Affibody (Alexa Fluor
532; red) conjugated to nanoparticles. After washing the nanoparticle-Affibody
bioconjugates, the fluorescent signal increases with an increased amount of fluorescent
Affibody (0-20 % Affibody/polymer molar ratio) on the nanoparticle surface confirming the
chemical conjugation efficiency. B) 1H-NMR (proton nuclear magnetic resonance) spectrum
represents the PLA-PEG-Affibody bioconjugates. The 1H-NMR spectrum shows the protons
assigned to the polymer (δ = 1-6 ppm) and the presence of Affibody polypeptide (δ = 7-8
ppm) confirming the chemical conjugation of the Affibody on the polymeric nanoparticles.
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Fluorescent microscopy of nanoparticle-Affibody bioconjugates incubated with HER-2
positive cell lines. Capan-1 cells, SK-BR-3 cells and SK-OV-3 cells were grown on chamber
slides and incubated in OptiMEM medium supplemented with 5 µg of NBD fluorescent dye
encapsulated into nanoparticles shown in green with (upper panel) or targeted nanoparticle-
Affibody bioconjugates (lower panel) for 2 hours prior imaging using fluorescent
microscopy at 60X magnification. The cell nuclei and the actin cytoskeleton are stained with
blue (4',6-diamidino-2-phenylindole) and red (Alexa-Flour Phalloidin-488), respectively.
The deconvoluted fluorescent images represent the mid-cross section of the cells after
washing (3 times), permeabilizing and staining steps.
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Combined fluorescent images (60X magnification) of a single SK-BR-3 cell to reconstruct a
three-dimensional image of the cell. A1-A4 (upper panel) images represent the mid-cross
section images of the same SK-BR-3 cell being rotated at 30-degree intervals along the y-
axis. A4 represents an image of SK-BR-3 rotated to 90-degree along the y-axis
demonstrating particles shown in green (NBD fluorescent dye encapsulated into the
nanoparticles) internalized inside the cell. The cell nuclei and the actin cytoskeleton are
stained with blue (4',6-diamidino-2-phenylindole) and red (Alexa-Flour Phalloidin-488),
respectively. B1-B4 (lower panel) represents fluorescent images of the same SK-BR-3
(shown in the upper panel) cell without the actin cytoskeleton staining confirming the
internalization of the nanoparticle-Affibody bioconjugates inside the cell.
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Cell viability assay (MTS assay) to evaluate the differential toxicity of targeted (Np-Affb)
and untargeted nanoparticles (Np) with and without encapsulated paclitaxel (Ptxl). In this
assay, the nanoparticle formulations were incubated for 2 hours, cells were subsequently
washed and incubated in cell growth media to allow the effect of the drug on the cell cycles
before quantifying the nanoparticle formulations toxicities against two cancer cell lines
expressing HER-2 (SK-BR-3 and SK-OV-3).ANNOVA test ”*” p<0.01; “**” p<0.05.
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